CinCor Pharma Inc. (CINC)
NASDAQ: CINC
· Real-Time Price · USD
29.06
0.00 (0.00%)
At close: Feb 23, 2023, 10:00 PM
Company Description
CinCor Pharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for cardio-renal diseases.
It is involved in developing CIN-107, which is in Phase II clinical trial for the treatment of hypertension, primary aldosteronism, and other cardio-renal diseases, as well as in Phase I clinical trial to treat chronic kidney diseases.
CinCor Pharma, Inc. has a license agreement with F.
Hoffman-La Roche Ltd. and Hoffmann-La Roche Inc.
The company was incorporated in 2018 and is headquartered in Boston, Massachusetts.
CinCor Pharma Inc.
| Country | United States |
| IPO Date | Jan 7, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Marc M. P. de Garidel |
Contact Details
Address: 200 Clarendon Street Boston, Massachusetts United States | |
| Website | https://www.cincor.com |
Stock Details
| Ticker Symbol | CINC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001868734 |
| CUSIP Number | 17240Y109 |
| ISIN Number | US17240Y1091 |
| Employer ID | 00-0000000 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Marc M. P. de Garidel | Chief Executive Officer & Director |
| Catherine Pearce DHSc, M.B.A., MBA | Co-Founder & Chief Operating Officer |
| Michael W. Kalb CPA | Executive Vice President, Chief Financial Officer & Principal Accounting Officer |
| Dr. Mason W. Freeman M.D. | Chief Medical Officer |
| Hema Keshava | Corporation Controller |
| Ida Hatoum | Senior Vice President and Head of People, Talent & Culture |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 06, 2023 | 15-12G | Filing |
| Mar 03, 2023 | SC 13D/A | [Amend] Filing |
| Mar 01, 2023 | SC 13D/A | [Amend] Filing |
| Feb 28, 2023 | SC 13D/A | [Amend] Filing |
| Feb 28, 2023 | 4 | Filing |
| Feb 28, 2023 | SC 13D/A | [Amend] Filing |
| Feb 27, 2023 | 4 | Filing |
| Feb 27, 2023 | 4 | Filing |
| Feb 24, 2023 | 4 | Filing |
| Feb 24, 2023 | 4 | Filing |